| Literature DB >> 31480587 |
Márió Gajdács1,2, Edit Urbán3, Gabriella Terhes4.
Abstract
Similarly to other non-spore-forming Gram-positive anaerobes, members of the Actinomyces genus are important saprophytic constituents of the normal microbiota of humans. Actinomyces infections are considered to be rare, with cervicofacial infections (also known as 'lumpy jaw syndrome') being the most prevalent type in the clinical practice. Actinomycoses are characterized by a slowly progressing (indolent) infection, with non-specific symptoms, and additionally, the clinical presentation of the signs/symptoms can mimic other pathologies, such as solid tumors, active Mycobacterium tuberculosis infections, nocardiosis, fungal infections, infarctions, and so on. The clinical diagnosis of actinomycosis may be difficult due to its non-specific symptoms and the fastidious, slow-growing nature of the pathogens, requiring an anaerobic atmosphere for primary isolation. Based on 111 references, the aim of this review is to summarize current advances regarding the clinical features, diagnostics, and therapy of cervicofacial Actinomyces infections and act as a paper for dentistry specialists, other physicians, and clinical microbiologists.Entities:
Keywords: Actinomyces; actinomycosis; cervicofacial infection
Year: 2019 PMID: 31480587 PMCID: PMC6784480 DOI: 10.3390/dj7030085
Source DB: PubMed Journal: Dent J (Basel) ISSN: 2304-6767
Actinomyces species implicated in human infections [1,3,5,7,8,10,11].
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Species in represent >90% of species isolated from human infections; A. odontolyticus and A. meyeri are more frequently implicated in infections of the cervicofacial region, while A. gerencseriae and A. israelii are prevalent in all types of actinomycoses.
Clinical manifestations of Actinomyces infections [1,5,11,19,21,22,23,24,25,26,27,28,29,30,31].
|
| 40–60% |
|
| |
| Upper and lower mandibles | 50% |
| Cheeks | 10–15% |
| Chin | 10–15% |
| Submaxillary ramus and angle, mandibular joints | 5–10% |
| CNS (brain abscess, meningitis, meningoencephalitis, epidural abscess, subdural empyema) | 5–10% |
| Tongue, sinuses, middle ear, larynx, lachrymal pathways, and thyroid gland | 0–5% |
|
| 20–30% |
|
| 20–25% |
|
| 3–5% |
|
| 3–5% |
General and disease-specific risk factors for cervicofacial actinomycosis [1,5,11,19,21,22,23,24,25,26,27,28,29,41,42,43].
| General | Disease-Specific |
|---|---|
| Human Immunodeficiency Virus (HIV) infection or manifest AIDS | Erupting secondary teeth |
| Hematological malignancies or solid tumors | Poor dental hygiene |
| Organ transplantation (especially in case of the kidneys and lungs) | Dental caries |
| Use of monoclonal antibodies (e.g., anti-tumor necrosis-α-inhibitors, infliximab, etanercept) | Gingivitis |
| Cancer chemotherapy | Mucositis |
| Corticosteroid use | Dental extraction |
| Malnutrition | Introduction of dental implants |
| Diabetes | Cervicofacial surgery |
| Alcoholism | Traumatic injury |
| Smoking and/or inhalation of particles | Bisphosphonate therapy |
| Low socio-economic status | Radiation therapy |
| Seizure disorders | |
| Crohn’s disease | |
| Hereditary diseases (e.g., hereditary hemorrhagic telangiectasia, chronic granulomatous disease) | |
| Use of non-steroid anti-inflammatory drugs (NSAIDs) |
Figure 1Schematic diagnostic algorithm for the clinical diagnosis of Actinomyces infections (for detailed explanation, see Section 2, Section 3 and Section 4).
Therapeutic considerations for Actinomyces infections.
|
| |
|
|
|
| Penicillin G | Metronidazole * |
| Penicillin V | Aminoglycosides * |
| Ampicillin | Other β-lactam-β-lactamase-inhibitor combinations * |
| Amoxicillin | Penicillinase-stable penicillins |
| Piperacillin/tazobactam | First generation cephalosporins (cephalexin) |
| Second generation cephalosporins with anti-anaerobic activity (cefoxitin) | Aztreonam * |
| Third generation cephalosporins (ceftriaxone) | Sulfamethoxazole/trimethoprim * |
| Carbapenems | Fluoroquinolones * |
| Doxycycline | |
| Tigecycline | |
| Clindamycin | |
| Macrolides | |
| Chloramphenicol | |
|
| |
| Surgical debridement, drainage | |
| Photodynamic therapy | |
| Laser therapy | |
* Should be reconsidered in case of polymicrobial infections (e.g., Enterobacteriaceae, other anaerobes).